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Abstract
Purpose: To evaluate predictive factors for PSA bounce after
125I permanent seed prostate brachytherapy and
identify criteria that distinguish between benign bounces and biochemical relapses.
Materials and methods: Men treated with exclusive permanent
125I seed brachytherapy from November 1999,
with at least a 36 months follow-up were included. Bounce was defined as an increase ≥ 0.2 ng/ml above the
nadir, followed by a spontaneous return to the nadir. Biochemical failure (BF) was defined using the criteria of the
Phoenix conference: nadir +2 ng/ml.
Results: 198 men were included. After a median follow-up of 63.9 months, 21 patients experienced a BF, and 35.9%
had at least one bounce which occurred after a median period of 17 months after implantation (4-50). Bounce
amplitude was 0.6 ng/ml (0.2-5.1), and duration was 13.6 months (4.0-44.9). In 12.5%, bounce magnitude exceeded the
threshold defining BF. Age at the time of treatment and high PSA level assessed at 6 weeks were significantly
correlated with bounce but not with BF. Bounce patients had a higher BF free survival than the others (100% versus
92%, p = 0,007). In case of PSA increase, PSA doubling time and velocity were not significantly different between
bounce and BF patients. Bounces occurred significantly earlier than relapses and than nadir + 0.2 ng/ml in BF patients
(17 vs 27.8 months, p < 0.0001).
Conclusion: High PSA value assessed 6 weeks after brachytherapy and young age were significantly associated to a
higher risk of bounces but not to BF. Long delays between brachytherapy and PSA increase are more indicative of BF.
Keywords: Brachytherapy, 125 iodine permanent seeds, Prostate cancer, PSA, Bounce, Biochemical relapse
Introduction
Permanent seed prostate brachytherapy has become a
standard treatment for localized prostate cancer [1,2]. The
follow up of patients treated with this technique is mainly
based on PSA screening, with PSA levels decreasing slowly
over years to a nadir. The value of the nadir has been cor-
related with patient clinical outcome, which has led some
authors to propose a threshold for defining biochemical
complete response (i.e. 0.5 ng/ml for patients with at least
6 years follow-up), but no consensus has been reached on
this issue for a long time [3-5]. The American Society for
Therapeutic Radiology and Oncology (ASTRO) consensus
conference held in San Antonio in 1997 defined biochem-
ical failure after exclusive adjuvant external beam radio-
therapy (EBRT) of the prostate as three consecutive
increases in PSA levels [6]. According to this definition,
date of relapse was calculated retrospectively as the mid-
way between the date of nadir and the date of the first
ascent of PSA. However, many criticisms were made on
this back dating system, and on the fact that this definition
did not account for clinical progression or survival and
was not applicable in case of associated hormonal therapy.
In 2006, the RTOG-ASTRO Phoenix consensus confer-
ence defined biological failure as a rise of 2 ng/ml or more
above the PSA nadir [7]. This definition was rapidly
assessed and was proposed in 2006 for use in prostate
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prostate brachytherapy may be disrupted by the occur-
rence of PSA bounces, defined as a transient increase of
the PSA value with spontaneous correction, which are fre-
quent after prostate brachytherapy and may mimic or be
mistaken for recurrences when strictly applying biochem-
ical failure definitions.
The main objectives of this study were to identify pre-
dictive factors of bounce occurrence and criteria distin-
guishing bounces from true biochemical relapses.
Methods and material
Prostate brachytherapy with permanent iodine seeds was
first used at the Centre Léon Bérard in November 1999
and so far more than 500 patients have been treated. In
order to investigate PSA bounces and obtain a significant
follow-up, our study population included all the men for
prostate carcinoma classified in the low or intermediate
group according to D’Amico et al. classification [9], with
at least 36 months follow-up. Patients who received hor-
monal therapy or additional EBRT were excluded.
Procedure
Two different brachytherapy techniques were consecu-
tively used: a free seeds technique with use of the Mick
applicator during the first 3 years, then the “FIRST” tech-
nique from Nucletron (Veenendall, The Netherlands)
characterized by the use of a seed projector. During both
periods, the prescribed dose was 160 Gy to the entire
prostate (applying TG43 guidelines) and an intra-operative
dosimetry was performed based on ultrasound delineation
of the prostate and organs at risk. PSA testing were per-
formed 6 weeks and 6 months after the brachytherapy,
then every 6 months up to 5 years, and at least once a year
thereafter. The frequency of PSA testing was usually
increased to every 3 months for patients who experienced
a PSA increase.
Definitions
As suggested by the majority of authors, PSA bounce was
defined as an increase of at least 0.2 ng/ml above the
nadir, followed by a spontaneous decrease to or below
pre-bounce level [10-22]. An isolated increase in PSA at
the first time point, 6 weeks after implantation, was not
considered as a bounce and PSA values corresponding to
visits earlier than 3 months after brachytherapy were not
taken into account in bounce screening. Alternative defi-
nitions of the bounce were applied for the description of
the bounces (+0.1, +0.4 and +2 ng/ml), but the analysis
were done using +0.2 ng/ml.
T h ed u r a t i o no ft h eb o u n c ew a sd e f i n e da st h et i m e
from the pre-bounce nadir to the first PSA level below
this nadir. The magnitude of the bounce was defined as
the difference between the nadir and the highest value
of the peak. Time to onset was assessed by delay
between brachytherapy and date corresponding to the
first date where PSA increased by more than 0.2.
Biochemical relapse was defined according to Phoenix
criteria (PSA nadir + 2 ng/ml). True biochemical relapse
was defined as a PSA increase fulfilling Phoenix criteria
but not bounce definition (spontaneous PSA decrease)
or post-brachytherapy positive biopsy or start of a sal-
vage treatment. In case of patients with a bounce and
then a true biochemical relapse, data were treated in the
analysis of bounce and relapse. In the case of patients
having two or more bounces, only the first one was
used for analysis.
PSA velocity (PSAV) and PSA doubling time (PSADT)
were calculated with formula: PSAV = (PSAf - PSAn)/ΔT
and PSADT = ln(2) ΔT/(ln(PSAf) - ln(PSAn)) where ΔTi s
the delay between PSAn (nadir) and PSAf (date of peak for
bounce patients or date of true biochemical relapse). Date
of true biochemical failure was defined as the delay between
brachytherapy and the first date where PSA is higher than 2
ng/ml from the nadir, the date of post-brachytherapy posi-
tive biopsy or the date of start of a salvage therapy.
Statistical analysis
True biochemical relapse-free survival delay was calcu-
lated from the date of the brachytherapy to the date of
relapse. The probability of true biochemical relapse-free
survival was calculated using the Kaplan-Meier method.
Clinical or dosimetric factors possibly predictive of
bounces were assessed by logistic regression. Factors
included in the univariate analysis were: patient age,
tumour risk group according to D’Amico et al. classifi-
cation (low vs. intermediate), pre-BT PSA, PSA value
assessed 6 weeks after the brachytherapy, brachytherapy
technique (free seeds vs. FIRST) and intra-operative
dosimetric parameters (prostate volume, V144, D95,
D90, total number of seeds and seeds density).
Potential predictive factors of bounces with a 0.1 sig-
nificance level in univariate analysis were included in a
multivariate logistic regression.
These factors were also tested to predict presence of
true biochemical relapse with a logistic regression model.
Bounce patients were compared to patients with true
biochemical relapse: PSAV, PSADT, nadir before rise
and time to onset were tested with a wilcoxon test. In
case of patients with bounce and relapse, they were con-
sidered only with bounce for this comparison.
All statistical analyses were done using SAS software
v.9.1 for Microsoft Windows (SAS Institute, Cary, NC,
USA).
Results
198 men fulfilled the inclusion criteria and were included
in the study. Their characteristics are detailed in Table 1.
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Page 2 of 12Median age was 67 years (49-80). 69 patients were treated
with the free seeds technique and 129 with the FIRST tech-
nique. The majority of the patients were classified in the
low risk group according to D’Amico et al. classification
(71.2%), and the others in the intermediate group.
The median follow-up was 63.9 months (range 36 -
119.4), 88.4 months (range 36.3 - 95.6) for the former
implantation technique and 52.9 months (range 36 - 81.9)
for FIRST.
A total of 2,219 PSA values were recorded, with a med-
ian number of 10.5 per patient (range: 3 - 24). Figure 1
shows distribution of PSA values at each visit.
At the first visit, scheduled 6 weeks after the brachyther-
apy (median 6.4 weeks, range 4.1 - 9.7), 20% of the
patients had a PSA increase from its initial value (median
increase: 0.83 ng/ml, range: 0.1 - 5.2). This value was not
taken into account in bounce identification as it may have
been altered by implantation and prostate edema.
At the time of analysis, 80.3% of the patients had
achieved a nadir < 0.5 ng/ml.
Bounces
Seventy one patients (35.9%) experienced at least one
bounce defined by a PSA increase of at least 0.2 ng/ml
followed by a spontaneous decrease to or below pre-
bounce level. Ten patients experienced 2 bounces and
one patient experienced 3 bounces. The respective
proportion of bounces defined as a PSA increase with a
threshold of 0.1, 0.4 and 2 ng/ml followed by a decrease
to or below pre-bounce level were 48.5, 25.8 and 4.5%
respectively. Characteristics of the bounces are pre-
sented in Table 2.
Median time to onset was 17 months (3.6-50.2), and
56.3% of the bounces occurred between 12 to 24 months
after the brachytherapy. After 30 months, bounces were
rare (8.5%).
The median bounce duration was 13.6 months (range:
4.0-44.9), and 75% were limited to 20 months. 18.3% lasted
over 2 years. The median increasing part duration of the
bounces, which is the most agonizing, was 6.4 months (1.3-
23), and was limited in 75% of the bounces to 11 months.
The median magnitude was 0.6 ng/ml (0.2-5.1). It was
lower than 1 ng/ml in 72% of the cases, but higher than
2 ng/ml in 12.5% of the bounces (9 patients).
Predictive factors for bounces
In univariate analysis, younger age was significantly asso-
ciated with a higher probability of a bounce occurrence
(p = 0.003). There was also a trend for higher PSA value at
Table 1 Patients’ characteristics
Age Median (range) 67 (49-80)
IPSS status (before BT) mean (SD) 3.6 (3.5)
median (range) 3 (0-17)
P25-P75 1-5
Technique free seeds 69 (34.8%)
FIRST 129 (65.2%)
Risk group (D’Amico) Low risk 141 (71.2%)
Intermediate risk 57 (28.8%)
Pre-BT PSA median (range) 7.2 (0.4 - 18.4)
P25-P75 5.5 - 8.7
Per-op. dosimetric data
Prostate volume median (range) 35 (14 - 61.9)
P25-P75 27.8 - 40.4
D95% median (range) 166 (105-220)
P25-P75 154-180
D90% median (range) 182 (131-235)
P25-P75 171-195
V144Gy median (range) 98.4 (82.7-100)
P25-P75 96.8-99.5
# seeds median (range) 74 (40-120)
P25-P75 63-83
Seeds density (N/cc) median (range) 2.1 (1.5-4.0)
P25-P75 1.9-2.4
Figure 1 Aa n dB . Distribution of PSA values per visit for patients who
had bounce or relapsed. Figure 1A for bounce and B represents relapse.
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Page 3 of 126 weeks (p = 0.053) (Table 3 and Figure 2). Dosimetric and
clinical factors as well as initial PSA value and Gleason
score were not associated with bounce.
In multivariate analysis, younger age (p = 0.0016, HR =
0.93, CI95%: 0.888-0.972) and higher PSA value at 6 weeks
(p = 0.0197, HR = 1.17, CI95%: 1.025-1.327) were signifi-
cantly associated with a higher probability of a bounce
(Table 4). Patients with PSA bounce were significantly
younger (median age 66 years (range: 51-79) vs. 69 years
(49-80)) and had a higher PSA value at 6 weeks (median
5.2 ng/ml (0.6-11.3) vs. 4.3 (0.1-11.6)).
Biochemical failures
Strictly applying the RTOG-ASTRO Phoenix consensus
definition, 21 patients (10.6%) were considered to have a
biochemical relapse (nadir +2 ng/ml), resulting in a 4 year
relapse free survival (RFS) of 92% (CI95% = 87-95). Six
patients had salvage hormonal therapy (3 with positive
biopsies), including 2 who did not meet the BF criteria
(nadir +2 ng/ml).
In 9 cases, the PSA raise overcame the threshold of
2 ng/ml, but was followed by a spontaneous decrease to
or below pre-bounce level fulfilling bounce definition.
Thus, the “true recurrence rate” (true BF or salvage treat-
ment) was 7.1% (21 BF + 2 salvage therapy - 9 bounces =
14 pts) and a 4 year RFS of 95% (CI95% = 91-97).
Predictive factors for biochemical failures
“True recurrences” (definition above) occurred respectively
in 5 pts belonging to the intermediate risk group (8.8%)
a n di n9p t st ot h el o wr i s kg r o u p( 7 . 1 % )( p=0 . 6 8 6 ) .
In univariate analysis, no factor was found being pre-
dictive of true relapse. Results are shown in Table 4.
There was a better true biochemical relapse free survi-
val in patients who experienc e dab o u n c e( t r u er e l a p s e
free survival rate at 4 years: 100% vs 92%, logrank test:
p = 0.0066).
Of the 71 patients who experienced a bounce, only one
subsequently had a true biochemical relapse; he belonged
to the intermediate prognosis group. Hence, none of the
patients in the low risk prognosis group who had a bounce
experienced a true biochemical relapse. Moreover, none of
the patients who experienced a bounce > 2 ng/ml experi-
enced a true biochemical recurrence.
Biochemical failures vs. bounce
O n ep a t i e n te x p e r i e n c e dab o u n c ef o l l o w e db yat r u e
biochemical relapse. He was considered as bounce
patient here. Table 5 presents results of comparison
between the 71 bounces and the 14 true relapses.
Median PSADT was 11.5 months for the 71 patients
who experienced a bounce (range: 1.0-70.2) and 12.0
months for the 14 patients with a true recurrence with-
out bounce (range: 3.9-49.5). The median PSA velocity
was estimated at 0.11 ng/ml/month for patients experien-
cing bounce (range: 0.01-0.85) and 0.12 ng/ml/month for
patients with true relapse (range: 0.03-0.58). There was
no difference between groups.
T h em e d i a nn a d i rb e f o r et h er i s ew a s1 . 3 8n g / m l
(range: 0.02-6.6) for bounce patients and 1.00 (range:
0.04-3.04) for true relapse patients (p = 0.25).
Bounces occurred significantly earlier than true BF (17
months vs. 44 months, p < .0001). Furthermore, the
level of nadir + 0.2 ng/ml was reached significantly later
in true BF cases than in bounce: 27.8 versus 17 months
(p < 0.0001)
Table 2 PSA bounce characteristics according to bounce definitions
Nadir + 0.2 Nadir + 0.1 Nadir + 0.4 Nadir + 2 Nadir + 15% Nadir + 35%
N (%) 71 (35.9%) 96 (48.5%) 51 (25.8%) 9 (4.5%) 103 (52.0%) 72 (36.4%)
Delay
Mean (SD) 18.5 (9.0) 18.7 (9.3) 18.6 (10.9) 16.5 (6.6) 21.5 (11.9) 24.6 (14.3)
Median (range) 17.0 (3.6-50.2) 16.7 (3.6-59.2) 17.4 (3.6-78.5) 17.9 (3.6-24.2) 17.9 (3.6-76.8) 21.4 (3.6-78.5)
P25-75 12.4-23.2 12.3-23.6 12.5-22.8 15.1-20.0 12.7-27.8 11.9-24.5
Magnitude
Mean (SD) 1.0 (1.0) 0.7 (0.9) 1.2 (1.1) 3.2 (1.3) 0.7 (0.9) 0.9 (1.1)
Median (range) 0.6 (0.2-5.1) 0.4 (0.1-5.1) 0.8 (0.4-5.1) 2.5 (2.1-5.1) 0.4 (0.01-5.1) 0.6 (0.01-5.1)
P25-75 0.3-1.3 0.2-0.8 0.6-1.5 2.1-4.6 0.1-0.8 0.2-1.3
Duration
Mean (SD) 16.5 (8.5) 15.2 (8.0) 17.7 (9.2) 24.8 (13.0) 16.6 (9.5) 18.8 (10.8)
Median (range) 13.6 (4.0-44.9) 12.9 (3.2-44.9) 15.9 (4.0-44.9) 29.3 (6.2-44.9) 13.6 (3.2-58.5) 16.8 (3.2-58.5)
P25-75 10.8-20.3 9.9-18.5 10.8-23.4 13.6-34.1 10.8-19.8 11.9-24.5
Delay for ascension
Mean (SD) 7.9 (4.9 7.1 (4.7) 8.3 (5.2) 9.9 (5.9) 7.4 (4.9) 8.2 (5.6)
Median (range) 6.4 (1.3-23.0) 6.0 (0.4-23.1) 6.4 (1.5-23.0) 11.1 (3.0-19.0) 6.0 (0.4-23.1) 6.2 (0.4-23.1)
P25-75 4.4-11.0 3.7-8.3 4.4-11.1 4.9-11.8 3.7-10.6 3.8-11.7
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The long-known phenomenon of PSA bounce after pros-
tate brachytherapy can lead to patient anxiety, unnecessary
imaging exams or prostate biopsies, and even to inap-
propriate administration of salvage therapy. So far, the
bounce mechanisms are not understood and their etiology
unknown. It has been hypothetized to be linked to inflam-
mation, radiation prostatitis or vascular fibrosis. Recently
Kirilova et al. published prostate 3D MR spectroscopic
assessments during PSA bounce in patients treated with
permanent
125I seeds. They attempted to correlate the
topography of the initial disease with the metabolic activity
during the bounce and with the exact locations of local
relapses in 24 patients [23]. They observed diffuse meta-
bolic activity uncorrelated with residual malignancy or
initial tumor mapping, suggesting that bounce could be
related to inflammation.
Bounce definition
PSA measurement has been shown to be a reliable method
for monitoring but there is currently no consensual defini-
tion of a bounce. For most authors, bounces correspond
to any variation beyond a given threshold above the PSA
nadir, usually +0.2 ng/ml [10-22]. Alternative definitions
Table 3 Predictive factors for bounce (univariate and multivariate analysis)
Univariate analysis Multivariate analysis
Variables OR CI 95% p OR CI 95% p
Age 0.936 0.895-0.978 0.0032 0.929 0.888-0.972 0.0016
PSA at 6 weeks (wks) 1.129 0.999-1.276 0.0526 1.166 1.025-1.327 0.0197
Pre-BT PSA 1.044 0.941-1.157 0.4190 - - -
Risk group (D’Amico) Int. risk vs low risk 1.180 0.625-2.229 0.6097 - - -
BT technique FIRST vs Free seeds 0.666 0.364-1.217 0.1865 - - -
Increased PSA at 6 wks Yes vs no 1.069 0.511-2.237 0.8584 - - -
Dosimetric data D95 (D95) 1.009 0.994-1.024 0.2591 - - -
D90 (D90) 1.007 0.990-1.023 0.4227 - - -
V144 (V144) 1.075 0.954-1.211 0.2351 - - -
Prostate volume 0.992 0.960-1.024 0.6166 - - -
# seeds 0.997 0.975-1.019 0.7775 - - -
Seed density 1.187 0.490-2.877 0.7037 - - -
Figure 2 6 week PSA value according to patients outcome: BF or bounce.
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Page 5 of 12have also been used: 0.1 or 0.4 ng/ml or an elevation com-
pared to the previous nadir, presented as a ratio: 15% or
35% [15,24,25]. The definition should take into account
physiologic fluctuations and laboratory assay variability.
One standard deviation has been evaluated as 0.1 ng/ml.
Depending on the definition applied bounce occurrence is
highly variable and ranges from 2.5 to 88% (Table 6)
[10-22,24-34]. However, three studies focusing on bounces
and applying similar inclusion criteria (no additional pelvic
EBRT or hormonal therapy) and similar bounce definition
reported closer bounce rates, between 37 and 50% (details
in Table 7) [14,21,34]. From those studies, the highest
bounce rate was reported by Zwahlen et al. who included
early PSA assessments in their analysis whereas we
excluded the 6 week value from the bounce search as we
consider that this value could be increased by the edema
due to the seed implantation. This could be an explanation
to their high bounce rate. The incidence and the time to
occurrence of bounces may also be closely related to the
frequency of PSA assessments after the brachytherapy,
explaining some fluctuations. In that way, Caloglu et al.
looking for a predictive factor of bounce occurrence
showed that the number of PSA assessed per year was sig-
nificantly correlated with bounce in multivariate analysis
(1.8 vs 1.7, p = 0.014) [26].
Predictive factors for bounce occurrence
Age is the most commonly reported predictive factor for a
bounce (Table 6). It seems that young age could be corre-
lated to bounce occurrence, and different thresholds have
reported, from 60 to 70 years old. Critz et al. showed that
patients who were ≤ 60 years old have a two fold risk of
bounce than the patients ≥ 71 years old (57% vs 26%, p <
0.0001) [27]. Similarly in a recent report Thompson et al.
showed that 60% of the observed PSA bounces occurred
in young patients (≤ 59 years old), whereas they account
for only 22% of true BF [31]. Age may, therefore, also have
influenced the differences in reported bounce rates. How-
ever, patients seemed to be similarly aged in the study by
Crook and ours: 66 years old (50-80) versus 67 (49-80)
[14]. In the series by Mitchell, patients were younger
(median: 62.1, 43-75) and the bounce rate was slightly
higher, 37% [14,21].
Prostate volume (> 35 ml) has been identified as predic-
tive of bounce by Stock et al. (23 versus 11% at 5 years,
p = 00.1), but this correlation has not been observed by
the other authors [25]. The transition zone volume to total
prostate volume ratio has been assessed in two studies. A
low ratio was significantly associated with bounce in the
study by Merrick et al. [20], but no correlation was
reported by Crook et al. [14]
Das et al. tried to correlate PSA bounce to various
events. They reported that 23% of the bounces may be
subsequent to ejaculation, cycling, invasive exams, or
radiation proctitis, [15] but those are not supported by
scientific evidence.
Intra-operative and post-brachytherapy dosimetric fac-
tors have also been largely studied. Stock et al. found
that D90 > 160 Gy was predictive of bounce (38% versus
2 4 %a t5y e a r s ,p=0 . 0 4 )[ 2 5 ] .T o l e d a n oe ta l .r e p o r t e d
similar results with a higher threshold, 200 Gy [32,33].
Recently, Kanai et al. found in a multivariate analysis
that high D90 was correlated with bounce occurrence
Table 4 Predictive factors for true recurrence (univariate
analysis)
Univariate analysis
Variables OR CI 95% P
Age 1.001 0.927-1.082 0.9734
PSA at 6 weeks (wks) 1.158 0.943-1.422 0.1626
Pre-BT PSA 1.081 0.907-1.287 0.3859
Risk group (D’Amico) Int. risk vs low risk 1.260 0.411-3.863 0.6864
BT technique FIRST vs Free seeds 0.586 0.203-1.690 0.3222
Increased PSA at 6 wks Yes vs no 1.519 0.456-5.063 0.4964
Dosimetric data D95 (D95) 0.989 0.962-1.017 0.4329
D90 (D90) 0.985 0.956-1.015 0.3296
V144 (V144) 0.965 0.805-1.156 0.6972
Prostate volume 0.966 0.908-1.027 0.2681
# seeds 0.966 0.926-1.009 0.1176
Seed density 1.208 0.249-5.848 0.8145
Table 5 Comparison between true biochemical relapse vs
bounce
Bounce True relapse p
N7 1 1 4
Delay
Mean (SD) 18.5 (9.0) 51.0 (22.3)
Median (range) 17.0 (3.6-50.2) 44.0 (15.6-89.6) < .0001
P25-75 12.4-23.2 35.7-70.8
PSA doubling time
Mean (SD) 14.8 (13.3) 15.9 (14.3)
Median (range) 11.5 (1.0-70.2) 12.0 (3.9-49.5) 0.995
P25-75 6.5-18.6 6.9-15.6
PSA velocity
Mean (SD) 0.2 (0.2) 0.2 (0.1)
Median (range) 0.1 (0.01-0.9) 0.1 (0.03-0.6) 0.424
P25-75 0.1-0.2 0.1-0.2
PSA nadir before increase
Mean (SD) 1.6 (1.2) 1.2 (0.9)
Median (range) 1.4 (0.02-6.6) 1.0 (0.04-3.0) 0.250
P25-75 0.8-2.3 0.5-1.9
Delay where nadir +0.2
Mean (SD) 18.5 (9.0) 31.5 (15.6)
Median (range) 17.0 (3.6-50.2) 27.8 (7.8-61.7) < .0001
P25-75 12.4-23.2 19.6-38.5
Mazeron et al. Radiation Oncology 2012, 7:46
http://www.ro-journal.com/content/7/1/46
Page 6 of 12Table 6 PSA bounce in literature
Authors Pub N Median
Follow-up
(months)
Hormone
Therapy
(%)
EBRT
(%)
Bounce Def Rate
(%)
Time to
onset
(months)
Magnitude
(ng/ml)
Duration
(months)
Predictive factors
Aaltomaa
[10]
2009 444 81.6 yes (18) Yes
(4)
≥ 0.2 ng/ml 13 19.2 1.4 – Age < 65, risk group, PSA
nadir < 0.5
Bostancic et
al. [11]
2007 164 65 yes (37.2) no ≥ 0.2 ng/ml 26.9 18.9 0.5 8.7 Age,
125 I>
103 Pd *
Cavanagh
et al. [12]
2000 591 55 no yes ≥ 0.2 ng/ml 35.8 24.8 –– NC
Ciezki et al.
[13]
2006 162 73 yes (38.2) no ≥ 0.2 ng/ml 46.3 15 –– Age < 70 *
Caloglu [26] 2010 820 58 Yes (22.2) no ≥ 0.2 ng/ml
≥ 0.4
≥ 0.6
≥ 0.8
30.1
19.6
12.8
9.5
17.4
16.3
16.2
15.7
–– Age, N of PSAs
Critz et al.
[27]
2003 1,011 72 no all ≥ 0.1 ng/ml 41 18 0.4 9 Age
Crook et al.
[14]
2007 275 44 no no ≥ 0.2 ng/ml 40 15.6 0.76 6.8 Age *
Das et al.
[15]
2002 186 33 no yes
(25.8)
≥ 15% 62 26.4 0.6 12 –
Kanai et al.
[17]
2009 86 32 no no ≥ 0.4 ng/ml 33 15 0.6 – Age < 67, D90 > 180 Gy
Kuban et al.
[18]
2006 2,693 63 no no ≥ 0.2 ng/ml 17 – 0.9 14 –
Hinnen et
al. [16]
2011 975 78 ¤ Yes (19) no ≥ 0.2 ng/ml 32.3 19.2 –– –
Makarewicz
et al * [19]
2006 71 32 no Yes
(100)
≥ 0.2 ng/ml 31 13.5 0.28 – Age, i PSA, V200
McGrath et
al [28]*
2009 191 48 Yes (46%) no ≥ 0.1 ng/ml
≥ 0.2 ng/ml
≥ 0.4 ng/ml
≥ 2 ng/ml
44
34
21
3
– 0.2
0.3
0.6
2.6
15
–
–
25
–
Merrick et
al. [20]
2003 218 46 no yes
(57.1)
≥ 0.2 ng/ml 23.9 16.3 0.9 16 Age, TNM, V150
PSA post brachy
Mitchell et
al. [21]
2008 205 45 no no ≥ 0.2 ng/ml 37 14.8 0.91 – Age
Morita et al.
[29]
2004 200 35 no no ≥ 0.1 ng/ml 40 13 0.3 ––
Patel et al.
[22]
2004 295 38 yes (62.4) no ≥ 0.2 ng/ml 28 19.4 0.5 – Age < 65 *
Pickles et al.
[30]
2006 449 48 yes (70) no all 84 13 –– –
Satoh et al.
[24]
2008 388 – no no ≥ 0.1 ng/ml
≥ 0.4 ng/ml
≥ 35%
50.8
23.5
19.4
– 0.4 ––
Stock et al.
[25]
2003 373 48 no no ≥ 0.1 ng/ml
≥ 0.4 ng/ml
≥ 35%
31
17
20
19.5
19.5
20.5
–– Age < 65, prostate
volume > 35 cm
3
(bounce > 0.4)*
Thompson
[31]
2010 1,006 54 Yes (65.7%) no +2 then
nadir ≤ 0.5
ng/ml
2.5 20.6 –– Age
Toledano et
al. [32,33]
2006 295 42 yes (42.4) no ≥ 0.1 ng/ml
≥ 0.2 ng/ml
≥ 0.4 ng/ml
55
49
32
19 0.8 11.2 Age < 70, D90 > 200 Gy *
Zwahlen
[34]
2010 194 60 no no ≥ 0.2 ng/ml
≥ 0.4 ng/ml
≥ 15%
≥ 35%
50
34
11
9
14
14
16
15.5
05
0.8
1.9
2
12
13
18
21.5
Age
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Page 7 of 12[17]. Some have speculated that high doses could lead to
a greater likelihood of inflammatory and thus to PSA
bounce. This dose/bounce correlation was also conveni-
ent to explain the correlation between bounce occur-
rence and biochemical control. Conversely, in Merrick
et al.’s experience bounces are more likely associated
with a low V150 (< 55%) [20]. In most studies, as in
ours, authors failed to demonstrate a link between dosi-
metric factors and PSA bounce.
Pre-brachytherapy PSA value has not been correlated
with the occurrence of a bounce, except in Makarewicz’s
HDR brachytherapy experience. In this report, the inves-
tigators showed that patients who experienced a bounce
had greater pre treatment PSA value than the others
(16.7 ng/ml vs 14.7 ng/ml, p = 0.045) [19].
Nevertheless, Merrick et al. have reported a correlation
between a first high post treatment PSA value and the
occurrence of a bounce (1.2 ng/ml vs. 0.7, p < 0.001) [35],
but in that study, PSA was evaluated every 3-6 months
and the first evaluation date seemed to be variable. In our
series, PSA level was systematically assessed 6 weeks after
the implantation, and was shown to be highly predictive of
the occurrence of a bounce. Moreover, this parameter was
not correlated with the occurrence of a true biochemical
recurrence. Unfortunately, we did not identify any
threshold.
Dose rate/Isotope
Most of the studies were based on
125 I permanent
implantation. Merrick stated that the use of
103 Pd lead to
a half likelihood of bounce (17% versus 33%, p = 0.002)
[35]. Those results were confirmed in a randomized trial
comparing the use of
125 Ia n d
103 Pd led by Bostancic et
al. They have shown by multivariate analysis that
125 Ii s
significantly associated with a higher frequency of bounce
in hormone-naive patients (45.7% with
125 I vs. 14% with
103 Pd) and in patients receiving neoadjuvant hormonal
deprivation (respectively 28.1 and 20.7%) [11]. The dose
rate can also be modulated in brachytherapy by using
HDR. McGrath et al. reported similar rates between LDR
permanent seed brachytherapy (34%, n = 191) and exclu-
sive HDR brachytherapy (36%, n = 93) [28]. Similarly,
Makarewicz et al. reported equivalent bounce rate while
combining EBRT with HDR brachytherapy (31%, n = 31%)
[19].
Hormonal therapy
PSA bounce phenomenon and hormonal therapy is more
confusing as the spike could be a consequence of the end
of hormonal deprivation and of the testosterone recovery.
For Patel and Toledano, ADT had no influence either on
bounce rate or its magnitude [22,32]. Similarly, Ciezki et
al., observed similar bounce rates between ADT treated
patients (45%) and hormone naïve patients (48.4%, p =
0.67) [13]. Conversely, Pikles reported higher bounce
rates in the ADT group (89% versus 71%, p = 0.001) [30].
PSA bounce: a predictive factor for biochemical control?
It has been hypothesized that PSA bounce after bra-
chytherapy could be predictive of biochemical control,
whereas it is known to be correlated with biochemical
failure after EBRT. In a series of 4,838 patients treated
with EBRT, Horwitz et al. observed a bounce (defined as
a ≥ 0.4 ng/ml PSA increase) in 20% of cases, and this
bounce was independently correlated to biochemical
failure [36]. These results have been confirmed by sev-
eral other reports [37,38].
Patel et al. analyzed a series of 295 patients treated
with brachytherapy (combined with hormonal therapy
in 2/3 of the patients), with quite a short median follow
up of 38 months. They observed that the BF-free survi-
val assessed using the ASTRO consensus was 100% in
the bounce group (28% of the population) vs. 92% in
other patients (p = 0.018) [22]. In an other study by
Ciezki et al. with longer follow-up (73 months), bio-
chemical-free survival rates for patients who experienced
or not a bounce were respectively 96% and 79% (p =
0.015) using the ASTRO definition and 100% and 92%
(p = 0.004) using the Phoenix criteria [13]. Recently,
Hinnen et al. published a large study including 975
patients and showed a strong link between bounce and
outcomes. Ten years freedom from BF, disease free sur-
vival, and overall survival were respectively 90%, 99%
and 88% in case of bounce against 70%, 93% and 82%
for “no bounce” patients. They also reported only one
cancer death in the “bounce group” (0.32%), compared
with 40 (6.05%) in the no-bounce group [16]. Further-
more, Caloglu et al. tested several bounce definitions (≥
0.2, ≥ 0.4, ≥ 0.6, ≥ 0.8) and found that the only defini-
tion for which there was a significant difference in BF
free survival between bounce and no-bounce patients
Table 6 PSA bounce in literature (Continued)
Mazeron
(this study)
2012 198 64 no no ≥ 0.1 ng/ml
≥ 0.2 ng/ml
≥ 0.4 ng/ml
≥ 15%
≥ 35%
48.5
35.9
25.8
52
36.4
17 0.6 14 Age, PSA 6 weeks
*: series including patients treated with HDR brachytherapy. –: non reported in publication. ¤: mean Abbreviations: Pub year = date of publication; N = number
of patients; F-up, follow-up; Hormon, hormonal therapy. i PSA: pre treatment value of PSA. N of PSA: amount of PSA values recorded per patient
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Page 8 of 12Table 7 Similar studies in detail
Authors Year N Age FU %
bounce
≥ +2 ng/
ml
Delay Amplitude Nadir duration Bounce
cause
BF & bounce Alternative
definitions
Crook et al. [14] 2007 275 64 (45-
80)
44 40 15% 15.2 (3-29) 0.76 (0.21-
11.79)
– 6.8 (3-50) Age Delay –
Mitchell et al. [21] 2008 205 62 (43-
75)
45 37 7.5% 14.9 (1.7-
40.6)
0.91 (0.2-5.8) 1.4 (0.1-6.9) 11.3 (2.3-
32.5)
Age V PSA (using Phoenix def) –
Zwahlen et al. [34] 2010 194 62 (47-
75)
60 50 11.3% 14 (0-70) 0.5 (0.2-8.3) 0.1 (0-3.5) 12 (2-43) Age Delay ≥ 0.4 ng/ml: 34
≥ 15%: 11
≥ 35%: 9
Mazeron (this
study)
2012 198 67 (49-
80)
64 36 12.7% 17 (3.6-50.2) 0.6 (0.2-5.1) 1.4 (0.02-
6.6)
13.6 (4-44.9 Age 6 week PSA assessment
delay
≥ 0.1 ng/ml: 49
≥ 0.4 ng/ml: 26
≥ 15%: 52
≥ 35%: 36
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2was +0.2 ng/ml (5-year BF control rates: 97.7% vs 97%,
p = 0.0011) [26].
In our series, we observed only one biochemical relapse
after a PSA bounce in one patient who belonged to the
intermediate prognosis group. With 64 months follow-up,
the occurrence of a bounce was therefore statistically cor-
related to biochemical disease-free survival in the sub-
group of patients with “favorable prognosis” (p = 0.039).
Differentiate benign bounces from genuine biochemical
relapses
Distinguishing a benign PSA bounce from genuine bio-
chemical recurrences is a major issue. On one hand it
would reassure most patients with a PSA raise, and on the
other hand, permit detection of true relapses in order to
avoid expensive investigations such as 18-F choline PET/
CT or invasive biopsies. To date, only follow up permits
distinction of bounce from true BF. As illustrated in this
series, 4 patients experienced an increase of the PSA over
+2 ng/ml, and had begun a spontaneous decrease of their
PSA at the time of analysis (of more than 1 ng/ml for 2 of
them), but still could not be classified as bounces as the
PSA did not return to the nadir.
Despite these limitations, Phoenix criteria have appeared
to be more accurate than the ASTRO criteria to predict
clinical outcomes in prostate cancer patients treated with
either EBRT or BT [7].
Kuban et al. led a comparison of 12 different BF defini-
tions on a large series of 2,693 men treated with perma-
nent seed brachytherapy. They concluded that nadir +2
ng/mg provides the best sensitivity/specificity balance
(70% and 89% respectively) [18]. Pickles et al. came to the
same conclusion with a smaller cohort [30]. However,
using this definition as a surrogate for relapses still leads
to false positive results, especially because of the bounce
phenomenon. Crook and Mitchell reported 15% and 7.5%
false positives [14,21]. In our series, 9 cases (41% of the
patients who experienced a nadir + > = 2 increase) would
have been considered as biochemical failures by strictly
applying the Phoenix criteria. For those patients, prostate
biopsy cannot reliably distinguish between bounces and
biochemical relapses during the first 3 years. Reed et al.
reported 8 cases of patients who underwent biopsies as
their PSA level increased to 2.6 and 8.4 ng/ml above the
nadir, 9 to 25 months after the brachytherapy. Biopsies
showed residual cancer, but PSA spontaneously decreased
to previous level in all patients [39].
In order to take into account the lack of specificity of
the Phoenix criteria, several definitions have been pro-
posed. Patel et al. have simply suggested that a bounce
should never exceed the pretreatment PSA level [22].
This parameter could be appropriate for Mitchell’s series
where only one bounce exceeded the pretreatment level,
but it would have led to false positivity for recurrence in
7% of our bounce patients and 15% of those reported by
Crook et al., and therefore does not seem reliable [14].
Thompson et al. applied an alternative PSA bounce defi-
nition: Phoenix definition (+2 ng/ml) followed by a
spontaneous decrease to ≤ 0.5 ng/ml, threshold which
had been previously used by some authors as usefull cri-
terion. 44% of the BF were reclassified as bounces [31].
As described in most series, the large majority of the
bounces occur during the first 2 years. Based on this
observation, Ghilezian et al. recently proposed an alter-
native BF definition: nadir + 5 for the initial 24 months,
and then nadir +2. This definition might be a superior
predictor for biochemical failure in patients treated with
brachytherapy, particularly if aged < 60 years [40]. In
our series, applying such a definition would lead to only
one patient misclassified as BF.
In an attempt to differenti a t eb o u n c ef r o mt r u eb i o -
chemical relapse, several parameters have been tested.
Mitchell et al. reported a series of 205 patients, and
observed 79 bounces defined as an increase of ≥ 0.2 from
the nadir followed by spontaneous decrease to the nadir
value or under, and 6 Phoenix true biochemical relapses.
They found that PSA velocity was 0.08 ng/ml/month for
bounces versus 0.28 ng/ml/month for true Phoenix bio-
chemical relapses (p = 0.0005). Using the former ASTRO
criteria, they did not observe any significant differences.
The authors failed to demonstrate a predictive threshold
for PSADT [21]. PSA velocity and PSADT were not sig-
nificant in our study, possibly because of the lenghthy
time interval between PSA assessments at the time of
PSA raise (6 months), and the limited number of patients
experiencing a nadir +2 ng/ml increase.
Time to onset of PSA increase has been shown to be
useful to distinguish bounce and relapse. Merrick et al.
reported that 83% of the bounces occurred in the first 30
months following brachytherapy [20]. Ciezki et al. have
reported that failures occurred after a median of 22.3
months, using Phoenix biochemical failure definition,
whereas bounces occurred after a median of 15.1 months
(p = 0.013) [13]. Similarly, Crook et al. have observed
bounces at 15.2 months and failures at 30.9 months (p =
0.02) [14]. Our study confirmed the validity of this criter-
ion (17 versus 27.8 months, p < 0.0001). We also observed
that the whole misleading bounces, higher than 2 ng/ml (9
cases), occurred within the 24 first months of the follow-
up (median 17.9 months), whereas “true” BF occurred
from 15.6 months with a median delay of 44 months.
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